| HS Code | 935510 |
| Product Name | BOC-L-Alaninol |
| Cas Number | 79069-13-1 |
| Molecular Formula | C8H17NO3 |
| Molecular Weight | 175.23 g/mol |
| Iupac Name | tert-butyl N-[(2S)-1-hydroxypropan-2-yl]carbamate |
| Smiles | CC(CO)NC(=O)OC(C)(C)C |
| Inchi Key | NHTMWHFIXYTQOW-LURJTMIESA-N |
| Appearance | Colorless to pale yellow liquid |
| Purity | ≥98% |
| Boiling Point | 317.8 °C (predicted at 760 mmHg) |
| Flash Point | 145.9 °C |
| Density | 1.016 g/cm³ (predicted) |
| Refractive Index | 1.45 |
| Specific Rotation | [α]20/D = -6.5° (c=1 in methanol) |
| Solubility | Soluble in methanol, ethanol, chloroform, and dichloromethane; sparingly soluble in water |
| Storage Conditions | Store in a cool, dry place, under inert atmosphere, at 2-8 °C, protected from light |
As an accredited BOC-L-Alaninol factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | BOC-L-Alaninol is packaged in a glass bottle with a PTFE-lined cap, nitrogen-purged for stability, containing 25 g per unit. |
| Container Loading (20′ FCL) | 20' FCL: BOC-L-Alaninol loaded as palletized drums, secured and blocked, container sealed for safe transport. |
| Shipping | BOC-L-Alaninol is shipped as a non-hazardous chemical under standard conditions. It is packaged in a sealed, moisture-resistant container to maintain purity, and transported at ambient temperature. Avoid exposure to heat, strong oxidizers, and prolonged air contact. Handle with standard laboratory PPE to prevent skin and eye irritation. |
| Storage | Store BOC-L-Alaninol in a tightly sealed container, protected from moisture, light, and air. Recommended storage temperature is 2–8°C (refrigerated) in a cool, dry, well-ventilated area. Keep away from incompatible materials such as strong oxidizing agents. Avoid repeated opening to prevent degradation. Ensure proper labeling and follow manufacturer guidelines for stability. |
| Shelf Life | Shelf life is typically 2–3 years when stored tightly sealed in a cool, dry place away from light and moisture. |
In the manufacture of hydroxyethylamine transition-state peptidomimetics for HIV-1 protease inhibitor scaffolds, BOC-L-Alaninol—(S)-2-(Boc-amino)-1-propanol, CAS 79069-13-9, molecular formula C₈H₁₇NO₃, molecular mass 175.23 g·mol⁻¹—is consumed as a protected chiral amino alcohol that supplies the (2S)-aminopropanol backbone after activation to the corresponding aldehyde. The compound is not a formulation additive; charge ratios are expressed as molar equivalents relative to the coupling partner rather than as weight-percent loadings. In a representative hydroxyethylamine route, (S)-Boc-alaninal is generated from 1.0–1.05 mol equivalents of BOC-L-Alaninol with 1.1–1.5 mol equivalents of Dess-Martin periodinane in dichloromethane at 0–5 °C, then condensed with an intermediate epoxide or allyl metal species; excess alcohol above 1.05 eq is generally avoided because residual periodinane-derived by-products accelerate formation of N-Boc-alanine and dimeric aldol side products. Compliance for the downstream API intermediate falls under ICH Q7 Section 7.3 for defined production instructions and Section 11 for retained samples; residual solvent control follows ICH Q3C, and elemental impurity risk is assessed under ICH Q3D. Downstream processing on pilot scale is carried out in jacketed glass-lined stirred reactors with retreat-curve impellers at 80–120 rpm; after aqueous bicarbonate quench and dichloromethane extraction, the aldehyde solution is used within 4 h or stored at -20 °C under nitrogen because the enantiomerically labile aldehyde shows measurable racemization on standing. The resulting terminal product types are hydroxyethylamine dipeptide isosteres and transition-state peptidomimetic intermediates intended for clinical development of antiviral protease inhibitors; published data for this specific configuration is limited outside patent examples and CMC files.
For organocatalytic and asymmetric metal-catalyzed ligand preparations, BOC-L-Alaninol is first deprotected with hydrogen chloride in methanol or trifluoroacetic acid in dichloromethane to release L-alaninol hydrochloride; the free amino alcohol is then converted into 2-oxazolines by condensation with nitrile-functionalized carboxylic acid derivatives. The deprotection is conducted at 1.0 mol equivalent of BOC-L-Alaninol and 3.0–5.0 mol equivalents of HCl in methanol at 20–40 °C for 2–24 h; residual trifluoroacetic acid in the isolated salt is controlled below ICH Q3C Class 2 limits when the product is later used in European pharmaceutical development. In bis(oxazoline) formation, 2.0 mol equivalents of L-alaninol are condensed with 1.0 mol equivalent of a dicarboxylic acid or bis(nitrile) in chlorobenzene at 110–130 °C under Dean-Stark water removal; zinc chloride at 0.05–0.10 mol equivalent is used as Lewis acid catalyst. For industrial compliance, non-GMP ligand synthesis follows ISO 9001:2015 Section 8.5 for process control; if the resulting chiral ligand is used in a catalytic step for an API, the ligand itself is a raw material and is qualified under ICH Q7 supplier audit procedures. Process equipment includes glass-lined reactors fitted with azeotropic condensers and nitrogen inerting; moisture during cyclization is limited to ≤0.05% water in solvent by Karl Fischer titration because water hydrolyzes the nitrile intermediate. Terminal product types are enantiopure 2-oxazolines, bis(oxazoline) ligands, and phosphine-oxazoline ligand precursors used in asymmetric hydrogenation and allylic substitution.
Solution-phase and solid-supported synthesis of peptidyl aldehydes consumes BOC-L-Alaninol as a masked aldehyde equivalent at the C-terminus of peptide chains; the N-Boc protection prevents premature nucleophilic attack during chain elongation and is removed after aldehyde formation or before assay. In a representative solution route, the alcohol is anchored to a chlorotrityl resin or converted to a Weinreb amide via oxidation; for direct oxidation, Dess-Martin periodinane or sulfur trioxide-pyridine oxidation at 1.0–1.5 mol equivalents converts the terminal alcohol to N-Boc-L-alaninal without cleaving the Boc group. The aldehyde is condensed with peptide amines or amino acid esters at 1.0–1.2 mol equivalents; larger excess leads to aldol condensation side products and reduces crude purity below 90% by HPLC. Compliance for research-grade material is governed by ICH Q3C residual solvent guidance when the intermediate enters in vivo testing; analytical purity is measured by USP <621>-aligned HPLC, and enantiomeric excess is controlled at ≥99.0% by chiral stationary phase chromatography. Downstream production involves low-temperature oxidation in glass-lined equipment at -10–0 °C, aqueous work-up with citrate buffer, and final liberation of the peptide aldehyde with trifluoroacetic acid/triisopropylsilane; the aldehyde is isolated as a hemiketal or bisulfite adduct to prevent polymerization. Terminal product types are peptide aldehyde inhibitors for calpain, proteasome, and serine protease target validation; this application remains primarily preclinical because aldehyde chemotypes present metabolic stability challenges.
Storage and release protocols for BOC-L-Alaninol supplied to contract development and manufacturing organizations are defined around water exclusion, inert atmosphere packaging, and enantiomeric stability. The product is handled as a cGMP intermediate under ICH Q7 Section 10 for storage and distribution; each batch is released against a specification that typically includes assay ≥98.0% by HPLC, water ≤0.5% by Karl Fischer titration, residual solvent limits under USP <467>, and enantiomeric excess ≥99.0% by chiral HPLC. Because BOC-L-Alaninol is hygroscopic and the Boc group can undergo acid-catalyzed deprotection, packaging is performed under nitrogen with residual headspace oxygen ≤5% and desiccant loadings of 10–20% of net product mass; the compound is stored at 2–8 °C in sealed fluoropolymer or glass containers. As a molar charge ratio, the downstream user typically charges 1.0 mol equivalent of BOC-L-Alaninol per chiral site; in sequence extension or coupling, that ratio may be increased to 1.2 mol equivalents when the coupling partner is moisture-sensitive resin-bound material. Downstream production operations include thawing of solidified material under nitrogen, vacuum drying at 25–30 °C for 4–6 h, and transfer through calendered silicone or PTFE lines into reactor charging nozzles. Terminal product types are cGMP pharmaceutical intermediates, custom chiral building blocks, and research material for pilot API campaigns; the product is not released for direct use in finished pharmaceuticals.
| Control point | Acceptance criterion | Reference method |
|---|---|---|
| Assay | ≥98.0% area | USP <621> HPLC |
| Water content | ≤0.5% | Karl Fischer titration, USP <921> Method Ia |
| Enantiomeric excess | ≥99.0% | Chiral HPLC, EP 2.2.46 |
| Residual solvents | Class 2 limits | GC headspace, USP <467> |
| Headspace oxygen | ≤5% | Gas analysis, packaging line |
When medicinal chemistry groups require enantiopure 1,2-amino alcohol libraries for structure-activity relationship studies, BOC-L-Alaninol is converted to N-Boc-L-alaninal and then subjected to addition of organolithium, Grignard, or allyl indium reagents. The reaction is typically conducted with 1.0 mol equivalent of BOC-L-Alaninol oxidized by sulfur trioxide-pyridine at 0–5 °C; the organometallic nucleophile is charged at 1.2–1.8 mol equivalents in tetrahydrofuran at -78 to -40 °C. Higher nucleophile excess above 1.8 eq increases byproduct formation from direct attack on the Boc carbonyl. Compliance for medicinal chemistry applications generally falls under local occupational health and safety and EU REACH registrations; if the resulting amino alcohols are nominated as development candidates, ICH Q3C residual solvent and ICH Q3D elemental impurity assessments are triggered for the new chemical entity. Downstream processing uses cryogenic jacketed reactors with 10–20 L working volume in early scale-up; after addition, the reaction is quenched with saturated ammonium chloride and extracted with ethyl acetate, and the diastereomeric ratio is monitored by chiral HPLC with typical syn/anti ratios of 2:1 to 9:1 depending on the presence of Lewis acid additives. Terminal product types are enantiopure 1,2-amino alcohol scaffolds used in central nervous system and metabolic disease discovery programs; published data for this specific configuration is limited when nonstandard nucleophiles are used, and process suitability must be confirmed by calorimetric screening.
Competitive BOC-L-Alaninol prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
BOC-L-Alaninol is the common commercial designation for tert-butyl N-[(2S)-1-hydroxypropan-2-yl]carbamate, a chiral N-protected amino alcohol with the molecular formula C8H17NO3 and a molecular weight of 175.23 g/mol. The substance is registered under CAS 79069-13-9 and is traded as a laboratory reagent, custom synthesis intermediate, and bulk pharmaceutical intermediate. The white to off-white crystalline solid carries a free primary hydroxyl and a tert-butoxycarbonyl-protected amine; the hydroxyl remains available for esterification, sulfonate formation, oxidation, and displacement, while the Boc group suppresses competing amine nucleophilicity. The stereochemical descriptor at C-2 is (S); the opposite enantiomer is supplied as BOC-D-Alaninol. Commercial packaging ranges from amber glass bottles to fluoropolymer-lined fibre drums, with a nitrogen or argon headspace and desiccant. The product is not a formulated pharmaceutical; it is an intermediate whose lot-specific certificate of analysis must be checked against the intended chemistry because no harmonized model number or pharmacopeial monograph is assigned.
Bulk acceptance is controlled by certificate-of-analysis parameters that include assay, chiral purity, water content, residue on ignition, residual solvents, and specific rotation. Because no dedicated monograph exists, release methods are typically compendial adaptations. Organic purity is determined by gas chromatography with flame ionization detection on a 5% phenyl methylsiloxane capillary column; a common release criterion is ≥ 98.0% area. Chiral purity is assessed by normal-phase high-performance liquid chromatography on a polysaccharide-based Chiralpak AD-H column 250 mm × 4.6 mm, with an acceptance threshold of ≥ 99.0% enantiomeric excess. Water content is measured by coulometric Karl Fischer titration according to ASTM E203-16; residue on ignition is controlled below 0.10% using USP <281> or Ph. Eur. 2.4.14. Residual solvent screening against USP <467> focuses on tert-butanol and dichloromethane; the typical release limits are ≤ 0.5% and ≤ 0.06%, respectively. Optical rotation is measured in chloroform at 20 °C with a specification interval of −22.0° to −25.0° at c = 1; the value is solvent-dependent and cannot be compared directly with methanol or aqueous measurements. Method validation for non-compendial HPLC and GC procedures often follows ICH Q2(R1), with forced-degradation data used to establish peak purity and specificity.
| Parameter | Method / Standard | Typical acceptance criterion |
|---|---|---|
| Assay | GC-FID, 5% phenyl methylsiloxane capillary column | ≥ 98.0% area |
| Chiral purity | Chiral HPLC, Chiralpak AD-H 250 mm × 4.6 mm | ≥ 99.0% ee |
| Water | ASTM E203-16 Karl Fischer titration | ≤ 0.5% w/w |
| Residue on ignition | USP <281> / Ph. Eur. 2.4.14 | ≤ 0.10% |
| Residual tert-butanol | USP <467> headspace GC | ≤ 0.5% |
| Residual dichloromethane | USP <467> headspace GC | ≤ 0.06% |
| Specific rotation | Polarimetry, c = 1, CHCl3, 20 °C | −22.0° to −25.0° |
Because BOC-L-Alaninol has a weak chromophore, HPLC with charged aerosol detection or evaporative light scattering detection is used for non-volatile impurities; gas chromatography is used for volatile impurities such as L-alaninol and tert-butanol. The absence of a strong UV signal means that simple UV area-percent HPLC can under-report non-chromophoric process impurities. Release methods therefore combine GC-FID, Karl Fischer titration, residue on ignition, and chiral HPLC. In QC laboratories, direct Karl Fischer injection of hygroscopic solids can bias the result high; an oven method coupled to the titrator is used for routine batch release to avoid surface-moisture interference.
For kilogram-scale processing, BOC-L-Alaninol is charged into a glass-lined reactor or Hastelloy C-22 vessel for sulfonate formation; methanesulfonyl chloride in dichloromethane at 0–5 °C with triethylamine converts the hydroxyl to the mesylate. The addition is controlled over 30–60 min, and the jacket is kept below 10 °C to prevent heat accumulation. The resulting N-Boc-2-aminopropyl methanesulfonate is not typically isolated; it is quenched with 1 M hydrochloric acid, washed with saturated sodium bicarbonate and brine, and concentrated below 25 °C. The sulfonate is then displaced with nitrogen, sulfur, or carbon nucleophiles to generate protected 1,2-diamines, β-aminothioethers, or longer-chain amino alcohol derivatives. The C-2 stereocentre is generally retained under SN2 displacement, but inversion is possible with certain nucleophiles; chiral HPLC after derivatization is used to confirm that the enantiomeric excess remains ≥ 99.0% before further processing. When the required intermediate is N-Boc-L-alaninal, oxidation with Dess-Martin periodinane in dichloromethane at 20–25 °C is preferred over Swern conditions when acid-sensitive groups are absent, because the workup is simpler; the aldehyde is used immediately to avoid α-epimerization. In peptide and peptidomimetic routes, the Boc group is retained through coupling steps and removed later with trifluoroacetic acid or HCl in dioxane; cleavage in dichloromethane at 0–25 °C is generally complete within 1–4 h at 1–2 M acid strength. Residual tert-butanol from incomplete solvent stripping can depress the apparent assay by 1–3%; vacuum stripping at 40–45 °C and 10–20 mbar before release is therefore applied to bulk lots.
In a 500 L double-cone rotary vacuum dryer, charging BOC-L-Alaninol at ambient relative humidity above 60% has been observed to produce surface moisture and clumping that increase drying time. Pre-drying the dryer with nitrogen and limiting the open-charge interval to less than 30 min are practical countermeasures. Drying at 40–45 °C under 10–20 mbar typically reduces water content to ≤ 0.3% within 6–12 h, but milled material with a fine fraction may require longer cycles. Exposure to jacket temperatures above 80 °C for prolonged periods is not recommended because the Boc group eliminates isobutylene and carbon dioxide, generating L-alaninol and oligomeric impurities. The product is incompatible with strong aqueous acids, acid chlorides under heating, and prolonged exposure to formaldehyde; acid residues from previous trifluoroacetic acid campaigns must be verified absent by rinse testing. Storage stability is improved by sealing the dried solid under nitrogen with desiccant and maintaining the warehouse at 2–8 °C for long-term inventory; drum-level retest intervals are usually 12 or 24 months, depending on the supplier stability programme.
If a route contains a benzyl ester, benzyl ether, or alkene that cannot tolerate hydrogenolysis, BOC-L-Alaninol is selected instead of N-Cbz-L-alaninol because the Boc group remains intact under catalytic hydrogenation. The protecting-group mass contribution is lower: the Boc group adds 100.12 g/mol to L-alaninol, whereas the Cbz group adds 134.13 g/mol. At the same molar loading, this difference improves process mass intensity and reduces the final deprotection load. The Boc derivative lacks the strong UV chromophore of the Cbz group; therefore TLC and HPLC monitoring at 254 nm is less sensitive, and charged aerosol detection or low-wavelength detection at 205–210 nm is used. Boc is removed cleanly with 4 M HCl in dioxane or trifluoroacetic acid, while Cbz requires hydrogenolysis or more forcing acidic conditions. In multiproduct plants, residual benzyl chloroformate or benzyl alcohol from Cbz processing can contaminate Boc-destined batches; dedicated glass-lined equipment and verified cleaning with an HPLC rinse test are used when switching campaigns. The opposite enantiomer BOC-D-Alaninol is differentiated by chiral HPLC retention time inversion on a Chiralpak AD-H column and by the sign of optical rotation; a batch with unintended enantiomer contamination below the release limit is not suitable for diastereoselective steps.
| Attribute | BOC-L-Alaninol | L-Alaninol | N-Cbz-L-alaninol |
|---|---|---|---|
| Molecular weight | 175.23 g/mol | 75.11 g/mol | 209.24 g/mol |
| Protecting group | Acid-labile Boc | None | Hydrogenolysis-labile Cbz |
| UV detection | Weak | Weak | Strong at 254 nm |
| Removal method | TFA, HCl in dioxane | Not applicable | H2/Pd or strong acid |
| Operational constraint | Avoid heat above 80 °C | Free amine; requires pH control | Avoid reducing conditions |
Unlike unprotected L-alaninol, which is a colourless viscous liquid with high aqueous solubility and a free-amine odour, BOC-L-Alaninol is a crystalline solid handled through solids addition hoppers under nitrogen. The narrow melting range of commercial material is typically 57–61 °C; molten charging is possible but requires heated transfer lines and care to avoid thermal deprotection. The product is not used in aqueous alkaline solutions above pH 10 at elevated temperature; short aqueous washes are maintained below pH 9 to limit slow Boc hydrolysis. The crystalline solid is also easier to isolate by pressure filtration or centrifugation than unprotected L-alaninol, but residual solvent entrapment in the crystal lattice requires longer vacuum cycles than for the liquid analogue. Published data for continuous large-scale production of this specific amino alcohol is limited; most industrial use is batch-mode laboratory or kilo-scale manufacture, where the main process risks are residual solvent retention, enantiomeric drift, and premature deprotection caused by thermal or acidic excursions.